Inside One-Shot Therapy to Lower Bad Cholesterol

VERVE-102, an experimental one-time gene-editing therapy developed by Verve Therapeutics, reduced LDL or “bad” cholesterol by about 62% in an early-stage trial, with effects observed for up to 18 months.

Why Target PCSK9?

• PCSK9 is a liver-produced protein that regulates LDL cholesterol levels in the bloodstream.
• People with naturally occurring loss-of-function mutations in PCSK9 tend to have very low LDL levels and reduced coronary heart disease risk.
• Existing PCSK9-blocking drugs have already demonstrated that suppressing this protein can produce large reductions in LDL cholesterol.

Early Trial Results

• The study reported roughly a 60% reduction in LDL cholesterol after a single infusion in treated patients.
• In the highest-dose group, PCSK9 levels fell by about 88% and LDL cholesterol by about 62% after four weeks.
• The average reduction in LDL cholesterol in the highest-dose group was approximately 78 mg/dL.

Potential Benefits

• A one-time therapy could help patients who struggle with daily tablets, repeated injections or long-term treatment adherence.
• Permanent LDL reduction could be particularly useful for people with familial hypercholesterolemia or very high cardiovascular risk.
• Gene editing could potentially provide sustained cholesterol control without requiring repeated lifelong medication.

Concerns and Limitations

• VERVE-102 has not yet been proven to directly reduce heart attacks or strokes, despite its strong LDL-lowering effect.
• Current follow-up extends only to about 18 months, which is insufficient to establish whether benefits and safety persist for decades.
• Because gene editing is intended to be permanent and irreversible, unexpected long-term effects would be difficult to reverse.
• Larger and more diverse clinical trials are needed before the treatment can be considered for widespread use.

Who Should Be Considered?

• Initial use is likely to focus on patients with familial hypercholesterolemia or exceptionally high cardiovascular risk.
• Wider use would depend on long-term evidence demonstrating safety, durability and reduction in cardiovascular events.